|
Post by neil36 on Jul 24, 2023 11:38:24 GMT -5
My guess is that UTHR and MNKD prices stablize and head higher from here. This (not insignificant!) news just posted on Seeking Alpha:
Shares of Liquidia Corporation (NASDAQ:LQDA) fell ~12% on Monday after the U.S. Court of Appeals for the Federal Circuit affirmed a district court ruling in a setback to the company’s patent dispute with United Therapeutics (NASDAQ:UTHR).
The decision comes after Liquidia (LQDA) appealed a Delaware district court ruling that found in August 2022 that the company infringed claims related to Patent No. 10,716,793 held by United Therapeutics (UTHR).
U.S. Patent No. '793 relates to treprostinil, which Liquidia (LQDA) intends to launch as an inhaled dry powder formulation for pulmonary arterial hypertension (PAH) and UTHR markets as Tyvaso.
|
|
|
Post by hellodolly on Jul 24, 2023 12:15:11 GMT -5
My guess is that UTHR and MNKD prices stablize and head higher from here. This (not insignificant!) news just posted on Seeking Alpha: Shares of Liquidia Corporation (NASDAQ:LQDA) fell ~12% on Monday after the U.S. Court of Appeals for the Federal Circuit affirmed a district court ruling in a setback to the company’s patent dispute with United Therapeutics (NASDAQ:UTHR). The decision comes after Liquidia (LQDA) appealed a Delaware district court ruling that found in August 2022 that the company infringed claims related to Patent No. 10,716,793 held by United Therapeutics (UTHR). U.S. Patent No. '793 relates to treprostinil, which Liquidia (LQDA) intends to launch as an inhaled dry powder formulation for pulmonary arterial hypertension (PAH) and UTHR markets as Tyvaso. The UTHR release is posted under the "Other BioPharma Stocks" - UTHR Thread
|
|
|
Post by MnkdWASmyRtrmntPlan on Jul 24, 2023 12:35:44 GMT -5
Thanks for researching that, Awesomo. Yeah, I'm not sure what to think of this. I totally agree with sayhey about him not understanding how to sell Afrezza. But, we are manufacturing another product now, and making good money for that, with more in the pipeline. Lucky Mike ... $1.5 million. Its a good job if you can get it. We can just hope that the studies all go well, kids spark Afrezza sales, and the adults will follow them ... Both T1 and especially T2.
|
|
|
Post by MnkdWASmyRtrmntPlan on Jul 24, 2023 12:50:29 GMT -5
What's with the 0.13 drop? Don't see any news. just taking a little break after an 11-day upward movement.
|
|
|
Post by jkendra on Jul 24, 2023 13:09:20 GMT -5
YEA!!! That's huge and great news. Thanks for finding and posting that, neil. So, this should mean that Liquidia will have to drop their Yutrepia product, no? Liquidia is down a buck today, but I think it should be down more than that. It is probably not done tanking yet. Why is MNKD not jumping? That makes no sense. Investors are not paying attention. No. Still have PTAB ruling.
|
|
|
Post by MnkdWASmyRtrmntPlan on Jul 24, 2023 13:15:54 GMT -5
Ah, right. I see that in another article. That's complicated legalease. I'm not sure if that was good or bad news today.
|
|
|
Post by jkendra on Jul 24, 2023 13:25:28 GMT -5
Check this article from 2022. From today's news, Liquidia was unable to reverse the district court decision. Liquidia is down to one more shot.
www.fiercepharma.com/pharma/united-therapeutics-lands-blow-inhaled-drug-patent-dispute-pushing-back-approval-genericUnited hailed the decision as a victory, noting that it expects the court to bar the FDA from granting final approval for Yutrepia until the ‘793 patent expires in 2027. Liquidia investors reacted negatively to the news, sending the company’s stock down 26% to around $4.30 when markets opened on Thursday. The decline followed another slump earlier in the week that added up to a 42% drop over five days. Yet, Liquidia still has two shots at bringing Yutrepia to market before 2027. In July, the USPTO’s Patent Trial and Appeal Board found that all the ‘793 claims are unpatentable. If the decision is upheld, Liquidia expects to be able to secure final FDA approval by mid-2024. That is one of two potential routes to a pre-2027 approval that are open to Liquidia. The other option is to seek and secure the reversal of the district court’s decision that Yutrepia infringes the ‘793 patent.
|
|
|
Post by Clement on Jul 24, 2023 13:31:50 GMT -5
YEA!!! That's huge and great news. Thanks for finding and posting that, neil. So, this should mean that Liquidia will have to drop their Yutrepia product, no? Liquidia is down a buck today, but I think it should be down more than that. It is probably not done tanking yet. Why is MNKD not jumping? That makes no sense. Investors are not paying attention. No. Still have PTAB ruling. Yes, today's news simply means that Yutrepia is delayed by months or maybe years, which is good news for T-DPI.
|
|
|
Post by MnkdWASmyRtrmntPlan on Jul 24, 2023 13:55:21 GMT -5
|
|
|
Post by hellodolly on Jul 24, 2023 14:27:27 GMT -5
YEA!!! That's huge and great news. Thanks for finding and posting that, neil. So, this should mean that Liquidia will have to drop their Yutrepia product, no? Liquidia is down a buck today, but I think it should be down more than that. It is probably not done tanking yet. Why is MNKD not jumping? That makes no sense. Investors are not paying attention. No. Still have PTAB ruling. What good is it it to them if they rule in favor of LQDA, but they are restricted from selling it until 2027? Did I miss something? Manufacture all you want, just can't sell it.
|
|
|
Post by Clement on Jul 24, 2023 14:42:33 GMT -5
No. Still have PTAB ruling. Yes, today's news simply means that Yutrepia is delayed by months or maybe years, which is good news for T-DPI. Here's a little more detail about the PTAB appeal: "Today’s ruling does not affect the decision by the Patent Trial and Appeal Board (PTAB) in July 2022, which the PTAB re-affirmed in February 2023, that all claims in the ‘793 patent are unpatentable as supported by the inter partes review (IPR) filed by Liquidia. UTHR has appealed the PTAB’s decision to the Federal Circuit and briefing should be completed in the fourth quarter of 2023. The Federal Circuit has ordered that oral arguments are to be heard after briefing is completed on the next available date in the oral argument calendar, which is expected to be in late fourth quarter 2023 to early 2024. Once argued, the Federal Circuit could rule within a few days after oral argument, in the case of summary affirmance, or within a few months after oral argument if a full written opinion is issued. If the Federal Circuit upholds the PTAB decision, then Liquidia will seek final regulatory approval for YUTREPIA." www.globenewswire.com/news-release/2023/07/24/2709832/0/en/U-S-Federal-Circuit-Affirms-All-District-Court-Rulings-in-Patent-Litigation.html
|
|
|
Post by peppy on Jul 24, 2023 15:04:24 GMT -5
MNKD Nasdaq real time volume, 1,757,188 ,the share count was 1,262,812 ten minutes prior to the close. $4.43 0.00% 0.00 UTHR. $245.73 1.01% -2.51 Today MNKD daily, schrts.co/xcTjIKpu$COMPQ daily, schrts.co/vfmpSRqK
|
|
|
Post by agedhippie on Jul 24, 2023 16:05:57 GMT -5
YEA!!! That's huge and great news. Thanks for finding and posting that, neil. So, this should mean that Liquidia will have to drop their Yutrepia product, no? Liquidia is down a buck today, but I think it should be down more than that. It is probably not done tanking yet. Why is MNKD not jumping? That makes no sense. Investors are not paying attention. No. Still have PTAB ruling. ^This. The PTAB and subsequent IPR have both ruled the patent invalid so that's done. UTHR are appealing that ruling and those appeals almost invariably fail unless the review didn't follow process which is exceptionally rare. If UTHR lose the appeal then the FDA will immediately grant approval and LQDA will start selling within a month or so. Right now LQDA is presenting papers, and has salesmen out talking to doctors in preparation for launch - they aren't standing still. The CEO of LQDA may have the charisma of a damp dishcloth, but he is extremely competent and was at UTHR for 18 years ending up as co-CEO with Martine. I have my popcorn for this one - www.liquidia.com/management/roger-jeffs
|
|
|
Post by jkendra on Jul 24, 2023 16:17:57 GMT -5
No. Still have PTAB ruling. ^This. The PTAB and subsequent IPR have both ruled the patent invalid so that's done. UTHR are appealing that ruling and those appeals almost invariably fail unless the review didn't follow process which is exceptionally rare. If UTHR lose the appeal then the FDA will immediately grant approval and LQDA will start selling within a month or so. Right now LQDA is presenting papers, and has salesmen out talking to doctors in preparation for launch - they aren't standing still. The CEO of LQDA may have the charisma of a damp dishcloth, but he is extremely competent and was at UTHR for 18 years ending up as co-CEO with Martine. I have my popcorn for this one - www.liquidia.com/management/roger-jeffsAnd what happens if United Therapeutics wins their case proving that trade secrets were stolen ? www.nccourts.gov/assets/documents/orders-of-significance/2023%20NCBC%20Order%2036.pdf?VersionId=CG5YCn5OABqzAvkEDj7vrSWWh4VDVa51
|
|
|
Post by prcgorman2 on Jul 24, 2023 16:30:17 GMT -5
No. Still have PTAB ruling. ^This. The PTAB and subsequent IPR have both ruled the patent invalid so that's done. UTHR are appealing that ruling and those appeals almost invariably fail unless the review didn't follow process which is exceptionally rare. If UTHR lose the appeal then the FDA will immediately grant approval and LQDA will start selling within a month or so. Right now LQDA is presenting papers, and has salesmen out talking to doctors in preparation for launch - they aren't standing still. The CEO of LQDA may have the charisma of a damp dishcloth, but he is extremely competent and was at UTHR for 18 years ending up as co-CEO with Martine. I have my popcorn for this one - www.liquidia.com/management/roger-jeffsYou answered one of my questions. What does the PTAB ruling mean if the courts say no? Courts already ruled, and upheld, LQDA infringed. I realize one court (two courts in this case) can say "infringed" and another court say "infringement is a moot point". I agree about the popcorn. It's always fun when you can have the USPO issue patents which are debated in courts which rule on the basis of the patents issued by the USPO who then decides, for whatever reasons, "Oh? Did we say these were patentable and issue patents? What we meant was, not patentable." Your tax dollars at play. Queue the circus music.
|
|